Sanofi-aventis Announces 2007 Earnings Ahead of Guidance Sharp Rise in Propose...(ne treatment for advancedovarian cancer ...),Health

Date:2/12/2008

ne treatment for advanced ovarian cancer is due to be completed in the second quarter of 2008. Aflibercept has a novel mechanism of action and its properties, as compared with monoclonal antibodies, give it the potential to be a more powerful anti-angiogenesis agent with a broader spectrum of activity.
Enrolment has started in 4 pivotal phase III studies:

-- first-line treatment of hormone refractory prostate cancer (in

association with Taxotere(R)/prednisone);

-- second-line treatment of colorectal cancer (in association with the

FOLFIRI regimen);

-- second-line treatment of non small cell lung cancer (in association

with Taxotere(R));

-- first-line treatment of pancreatic cancer (in association with

gemcitabine).

The TRIST study, evaluating the therapeutic vaccine TroVax(R) (collaboration with Oxford Biomedica) as a first-line treatment for metastatic renal cancer in association with interleukin-2, interferon or sunitinib, has enrolled 577 patients out of a target population of 700. In the second quarter of 2008, enrolment will begin as planned for a study evaluating TroVax(R) as a first-line treatment in association with FOLFOX or FOLFIRI (+/- bevacizumab) in 1,300 metastatic colorectal cancer patients. Submission in metastatic renal cancer is scheduled for 2009, and in metastatic colorectal cancer for 2013.

The phase III study evaluating the second-generation taxoid larotaxel as a second-line treatment for pancreatic cancer is under way, with 104 patients out of 430 enrolled to date. Filing for approval is scheduled for 2009.

Vaccines

At the end of 2007, sanofi-aventis filed for approval in Europe of the first influenza vaccine to use a new delivery system (intradermic micro- injection). Filing in the United States is scheduled for 2009.

A number of other influenza vaccine R&D programs made significant progress during 2007:
-- The improved formula
'/>"/>

SOURCE sanofi-aventis Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
Related medicine news :

1. Sanofi-Aventis renews licenses for Genomatix chip analysis pipeline
2. Sanofi-aventis US Chairman Tim Rothwell Addresses CMSAs Collaborative Practice Summit
3. Sanofi-aventis Announces a Good Third Quarter Performance; Increase in 2007 full-year earnings growth guidance
4. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
5. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. HEI, Inc. Announces Sale of RFID Division Assets
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
10. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
11. Brooke Franchise Corporation Announces Selected July Results